Amylyx Investors To Get $6.5M In ALS Drug Settlement
Amylyx Pharmaceuticals and a class of shareholders are seeking judicial approval for a $6.5 million settlement to resolve allegations that the drugmaker overstated the commercial potential of a treatment for amyotrophic...To view the full article, register now.
Already a subscriber? Click here to view full article